State Street Corp decreased its stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 4.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,277,841 shares of the company's stock after selling 61,236 shares during the period. State Street Corp owned 2.02% of Evolus worth $20,701,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in EOLS. Point72 Asset Management L.P. acquired a new stake in Evolus in the third quarter worth $132,000. Ikarian Capital LLC acquired a new stake in shares of Evolus in the 3rd quarter worth about $4,184,000. Caligan Partners LP lifted its position in Evolus by 1.2% in the 3rd quarter. Caligan Partners LP now owns 2,193,488 shares of the company's stock valued at $35,535,000 after purchasing an additional 25,698 shares during the last quarter. Walleye Capital LLC acquired a new position in Evolus during the 3rd quarter valued at about $3,438,000. Finally, BNP Paribas Financial Markets grew its position in Evolus by 99.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 62,748 shares of the company's stock worth $1,017,000 after purchasing an additional 31,300 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company's stock.
Evolus Price Performance
Shares of EOLS traded up $0.01 during midday trading on Tuesday, reaching $10.85. The stock had a trading volume of 277,690 shares, compared to its average volume of 589,118. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The company has a market capitalization of $687.03 million, a P/E ratio of -11.92 and a beta of 1.27. The firm's 50 day moving average price is $13.69 and its 200-day moving average price is $13.77. Evolus, Inc. has a 52 week low of $9.80 and a 52 week high of $17.82.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on the company. Barclays boosted their price objective on Evolus from $16.00 to $20.00 and gave the stock an "overweight" rating in a research report on Friday, September 13th. HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of Evolus in a research note on Thursday, November 7th. Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Evolus in a research note on Friday, September 13th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Evolus in a research report on Monday, September 16th.
Read Our Latest Research Report on EOLS
About Evolus
(
Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Further Reading
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
